Literature DB >> 24355646

Chronic thromboembolic pulmonary hypertension.

Nick H Kim1, Marion Delcroix2, David P Jenkins3, Richard Channick4, Philippe Dartevelle5, Pavel Jansa6, Irene Lang7, Michael M Madani8, Hitoshi Ogino9, Vittorio Pengo10, Eckhard Mayer11.   

Abstract

Since the last World Symposium on Pulmonary Hypertension in 2008, we have witnessed numerous and exciting developments in chronic thromboembolic pulmonary hypertension (CTEPH). Emerging clinical data and advances in technology have led to reinforcing and updated guidance on diagnostic approaches to pulmonary hypertension, guidelines that we hope will lead to better recognition and more timely diagnosis of CTEPH. We have new data on treatment practices across international boundaries as well as long-term outcomes for CTEPH patients treated with or without pulmonary endarterectomy. Furthermore, we have expanded data on alternative treatment options for select CTEPH patients, including data from multiple clinical trials of medical therapy, including 1 recent pivotal trial, and compelling case series of percutaneous pulmonary angioplasty. Lastly, we have garnered more experience, and on a larger international scale, with pulmonary endarterectomy, which is the treatment of choice for operable CTEPH. This report overviews and highlights these important interval developments as deliberated among our task force of CTEPH experts and presented at the 2013 World Symposium on Pulmonary Hypertension in Nice, France.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ACP; CT; CTEPH; CTPA; DHCA; ECMO; MRI; PAH; PAP; PEA; PH; PTPA; PVR; RCTs; VQ; antegrade cerebral perfusion; chronic thromboembolic pulmonary hypertension; computed tomography; computed tomography pulmonary angiogram; deep hypothermic circulatory arrest; extracorporeal membrane oxygenation; magnetic resonance imaging; percutaneous transluminal pulmonary angioplasty; pulmonary angiogram; pulmonary arterial hypertension; pulmonary artery pressure; pulmonary endarterectomy; pulmonary hypertension; pulmonary vascular resistance; randomized controlled trials; ventilation/perfusion; ventilation/perfusion scan

Mesh:

Year:  2013        PMID: 24355646     DOI: 10.1016/j.jacc.2013.10.024

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  113 in total

1.  Dyspnoea in a young woman: the opposite of every truth is just as true.

Authors:  Alberto Banzato; Marny Fedrigo; Gentian Denas; Giovanni Faggioni; Alessandra Bianchi; Marialuisa Valente; Vittorio Pengo; Annalisa Angelini
Journal:  Intern Emerg Med       Date:  2015-09-08       Impact factor: 3.397

2.  Abnormal Ventilation-Perfusion Scan Is Associated with Pulmonary Hypertension in Sickle Cell Adults.

Authors:  Alem Mehari; Norris Igbineweka; Darlene Allen; Jim Nichols; Swee Lay Thein; Nargues A Weir
Journal:  J Nucl Med       Date:  2018-06-07       Impact factor: 10.057

3.  Balloon pulmonary angioplasty: applicability of C-Arm CT for procedure guidance.

Authors:  Jan B Hinrichs; Julius Renne; Marius M Hoeper; Karen M Olsson; Frank K Wacker; Bernhard C Meyer
Journal:  Eur Radiol       Date:  2016-02-23       Impact factor: 5.315

4.  Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From the United Kingdom National Cohort.

Authors:  John E Cannon; Li Su; David G Kiely; Kathleen Page; Mark Toshner; Emilia Swietlik; Carmen Treacy; Anie Ponnaberanam; Robin Condliffe; Karen Sheares; Dolores Taboada; John Dunning; Steven Tsui; Choo Ng; Deepa Gopalan; Nicholas Screaton; Charlie Elliot; Simon Gibbs; Luke Howard; Paul Corris; James Lordan; Martin Johnson; Andrew Peacock; Robert MacKenzie-Ross; Benji Schreiber; Gerry Coghlan; Kostas Dimopoulos; Stephen J Wort; Sean Gaine; Shahin Moledina; David P Jenkins; Joanna Pepke-Zaba
Journal:  Circulation       Date:  2016-04-06       Impact factor: 29.690

Review 5.  Pulmonary hypertension 2015: current definitions, terminology, and novel treatment options.

Authors:  Stephan Rosenkranz
Journal:  Clin Res Cardiol       Date:  2014-12-06       Impact factor: 5.460

6.  Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Authors:  Diana Khaybullina; Ami Patel; Tina Zerilli
Journal:  P T       Date:  2014-11

Review 7.  State of the art: utility of multi-energy CT in the evaluation of pulmonary vasculature.

Authors:  Prabhakar Rajiah; Yuki Tanabe; Sasan Partovi; Alastair Moore
Journal:  Int J Cardiovasc Imaging       Date:  2019-05-02       Impact factor: 2.357

8.  Pulmonary hypertension nosography: are all patients classifiable?

Authors:  Elena Torricelli; Mariaelena Occhipinti; Federico Lavorini; Chiara Cresci; Chiara Arcangeli; Edoardo Cavigli; Francesca Bigazzi; Massimo Pistolesi
Journal:  Intern Emerg Med       Date:  2017-06-30       Impact factor: 3.397

9.  Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers.

Authors:  Aaron W Trammell; Meredith E Pugh; John H Newman; Anna R Hemnes; Ivan M Robbins
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

Review 10.  Can thrombus age guide thrombolytic therapy?

Authors:  Christopher Czaplicki; Hassan Albadawi; Sasan Partovi; Ripal T Gandhi; Keith Quencer; Amy R Deipolyi; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.